

New Research into the treatment of NMO/ NMOSD

Do you have NMO or NMOSD?

Have you experienced a relapse in the last 12 months?

If the answer to both of these questions is Yes, you may be able to take part in a new clinical research study.

The SAKura**Sky** study is looking at the safety and efficacy of an investigational medication for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder (NMO/NMOSD) that is given as an injection under the skin once a month along with your current therapy.

You may be eligible to take part in SAKura**Sky** the study if you:

- Are between 12 and 74 years of age, **and**
- Have been diagnosed with NMO or NMOSD, **and**
- Are currently being treated with one of the following agents:
 - Azathioprine, **or**
 - Mycophenolate mofetil, **or**
 - Oral corticosteroids
- Do not have any evidence of MS or other demyelinating disease, and
- Do not have an active infection (excluding fungal infections of nail beds or dental infection) within the last 4 weeks.

At each visit, the study team will monitor your symptoms and health. If you decide to participate in the study you will either receive the new investigational agent or a placebo injection. This study will last for about 18 months and will include visits once a month to the study center. You will be reimbursed for your travel expenses.

If you are interested in learning more about the SAKura**Sky** study, please contact:

SA237 Clinical Trial: sakuraskyinfo@chugai-pharm.co.uk

For more information on the trial, please visit:

<https://www.clinicaltrialsregister.eu/ctr-search/search?query=SA237%20>

